- Home
- EOD vs EDIT Comparison
EOD vs EDIT Comparison
Compare EOD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOD
- EDIT
- Stock Information
- Founded
- EOD 2007
- EDIT 2013
- Country
- EOD United States
- EDIT United States
- Employees
- EOD N/A
- EDIT N/A
- Industry
- EOD Investment Managers
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EOD Finance
- EDIT Health Care
- Exchange
- EOD Nasdaq
- EDIT Nasdaq
- Market Cap
- EOD 245.9M
- EDIT 269.8M
- IPO Year
- EOD N/A
- EDIT 2016
- Fundamental
- Price
- EOD $5.63
- EDIT $2.62
- Analyst Decision
- EOD
- EDIT Buy
- Analyst Count
- EOD 0
- EDIT 10
- Target Price
- EOD N/A
- EDIT $4.13
- AVG Volume (30 Days)
- EOD 118.1K
- EDIT 2.3M
- Earning Date
- EOD 01-01-0001
- EDIT 11-10-2025
- Dividend Yield
- EOD 9.28%
- EDIT N/A
- EPS Growth
- EOD N/A
- EDIT N/A
- EPS
- EOD N/A
- EDIT N/A
- Revenue
- EOD N/A
- EDIT $46,383,000.00
- Revenue This Year
- EOD N/A
- EDIT N/A
- Revenue Next Year
- EOD N/A
- EDIT N/A
- P/E Ratio
- EOD N/A
- EDIT N/A
- Revenue Growth
- EOD N/A
- EDIT N/A
- 52 Week Low
- EOD $3.73
- EDIT $0.91
- 52 Week High
- EOD $4.71
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- EOD 39.53
- EDIT 38.06
- Support Level
- EOD $5.63
- EDIT $2.45
- Resistance Level
- EOD $5.72
- EDIT $2.69
- Average True Range (ATR)
- EOD 0.07
- EDIT 0.21
- MACD
- EOD -0.02
- EDIT -0.03
- Stochastic Oscillator
- EOD 17.97
- EDIT 26.57
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.